Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

Key facts

Sponsor

Sichuan University

Principal Investigator

Rong Tian, MD

West China Hospital

Intervention

IR-101(drug)

Enrollment

10 enrolled

Eligibility

All sexes

Timeline

2025 – 2026

Study locations (2)

• West China Hospital, Chengdu, Sichuang, China
• West China Hospital, Chengdu, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT07549321
  A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
  Renaissance Pharma Ltd.
• RECRUITINGPHASE1, PHASE2NCT06625190
  Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
  University of Florida
• RECRUITINGPHASE1NCT07172958
  Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
  Children's National Research Institute
• RECRUITINGPHASE2NCT07085338
  A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
  St. Jude Children's Research Hospital
• RECRUITINGPHASE1, PHASE2NCT07399821
  An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
  Princess Maxima Center for Pediatric Oncology
• RECRUITINGPHASE1NCT06995872
  Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT06814496
  Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
  University of Arizona
• RECRUITINGPHASE1NCT07087002
  GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
  Stanford University

See all trials for Neuroblastoma →